This is what analysts have to say about Anika Therapeutics, Inc. (NASDAQ:ANIK) after last week.

March 2, 2018 - By Michael Collier

 This is what analysts have to say about Anika Therapeutics, Inc. (NASDAQ:ANIK) after last week.
Investors sentiment increased to 1.42 in Q3 2017. Its up 0.28, from 1.14 in 2017Q2. It is positive, as 11 investors sold Anika Therapeutics, Inc. shares while 42 reduced holdings. 23 funds opened positions while 52 raised stakes. 12.29 million shares or 0.38% more from 12.24 million shares in 2017Q2 were reported.
Gotham Asset Management Lc holds 0.04% in Anika Therapeutics, Inc. (NASDAQ:ANIK) or 42,927 shares. Mcf Advisors Limited holds 250 shares or 0% of its portfolio. Goldman Sachs Grp Inc has invested 0% in Anika Therapeutics, Inc. (NASDAQ:ANIK). 1,060 are owned by Us National Bank De. Swiss Fincl Bank owns 24,300 shares for 0% of their portfolio. Kennedy owns 23,825 shares or 0.02% of their US portfolio. Sector Pension Investment Board invested in 9,271 shares. One National Association has 5,896 shares. Alps Advsr has invested 0% of its portfolio in Anika Therapeutics, Inc. (NASDAQ:ANIK). Los Angeles Capital Mngmt And Equity Research invested in 0.01% or 22,076 shares. Ameriprise Fin Incorporated accumulated 119,209 shares. Metropolitan Life owns 10,417 shares. Citadel Advsrs Llc has invested 0% in Anika Therapeutics, Inc. (NASDAQ:ANIK). State Board Of Administration Of Florida Retirement Sys owns 7,943 shares for 0% of their portfolio. National Bank Of America Corp De reported 17,961 shares.

Since October 12, 2017, it had 0 insider buys, and 4 selling transactions for $2.52 million activity.

Anika Therapeutics, Inc. (NASDAQ:ANIK) Ratings Coverage

Among 4 analysts covering Anika Therapeutics (NASDAQ:ANIK), 2 have Buy rating, 0 Sell and 2 Hold. Therefore 50% are positive. Anika Therapeutics has $57 highest and $37 lowest target. $45.75’s average target is -11.18% below currents $51.51 stock price. Anika Therapeutics had 9 analyst reports since July 30, 2015 according to SRatingsIntel. The stock of Anika Therapeutics, Inc. (NASDAQ:ANIK) has “Market Perform” rating given on Friday, February 23 by Barrington Research. The stock has “Hold” rating by Zacks on Wednesday, August 26. The stock of Anika Therapeutics, Inc. (NASDAQ:ANIK) has “Overweight” rating given on Wednesday, January 24 by First Analysis. The stock of Anika Therapeutics, Inc. (NASDAQ:ANIK) has “Outperform” rating given on Thursday, July 30 by Northland Capital. The firm earned “Market Perform” rating on Wednesday, April 27 by Northland Capital. Northland Capital maintained Anika Therapeutics, Inc. (NASDAQ:ANIK) rating on Friday, February 26. Northland Capital has “Outperform” rating and $50 target. Barrington Research initiated the stock with “Outperform” rating in Monday, October 12 report. First Analysis initiated the stock with “Equal Weight” rating in Friday, August 28 report. Below is a list of Anika Therapeutics, Inc. (NASDAQ:ANIK) latest ratings and price target changes.

23/02/2018 Broker: Barrington Research Old Rating: Outperform New Rating: Market Perform Downgrade
24/01/2018 Broker: First Analysis Old Rating: Equal-Weight New Rating: Overweight Upgrade
28/12/2017 Broker: Barrington Rating: Buy New Target: $57.0

The stock decreased 1.04% or $0.54 during the last trading session, reaching $51.51. About 124,913 shares traded or 51.72% up from the average. Anika Therapeutics, Inc. (NASDAQ:ANIK) has risen 4.53% since March 2, 2017 and is uptrending. It has underperformed by 12.17% the S&P500.

Anika Therapeutics, Inc., together with its subsidiaries, provides orthopedic medicines for patients with degenerative orthopedic diseases and traumatic conditions in the United States and internationally. The company has market cap of $755.23 million. The firm develops, makes, and commercializes therapeutic products based on its proprietary hyaluronic acid technology. It has a 24.41 P/E ratio. The Company’s orthobiologics products comprise ORTHOVISC, ORTHOVISC mini, MONOVISC, and CINGAL for the treatment of osteoarthritis of the knee; HYALOFAST, a biodegradable support for human bone marrow mesenchymal stem cells used for cartilage regeneration and as an adjunct for microfracture surgery; HYALONECT, a woven gauze used as a bone graft wrap; HYALOSS used to mix blood/bone grafts to form a paste for bone regeneration; and HYALOGLIDE, an ACP gel used in tenolysis treatment.

More notable recent Anika Therapeutics, Inc. (NASDAQ:ANIK) news were published by: Businesswire.com which released: “Anika Therapeutics Announces Strategic Collaboration with the Institute of …” on February 01, 2018, also Gurufocus.com with their article: “Anika Therapeutics Inc (ANIK) Files 10-K for the Fiscal Year Ended on December …” published on February 27, 2018, Benzinga.com published: “Anika Therapeutics Shares Stunted By Increased Investment, Barrington Says In …” on February 23, 2018. More interesting news about Anika Therapeutics, Inc. (NASDAQ:ANIK) were released by: Seekingalpha.com and their article: “Anika Therapeutics’ (ANIK) CEO Charles Sherwood on Q4 2017 Results – Earnings …” published on February 22, 2018 as well as Businesswire.com‘s news article titled: “Anika Reports Fourth Quarter and Full Year 2017 Financial Results” with publication date: February 21, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.